FREE SHIPPING ON ORDERS OVER $150

glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology Glutathione transporter as a target

$26.13

Quantity
- +
Description

All commercial syntheses are based on the concept of a three-component, one-pot reaction of triamino-pyrimidinone with a three-carbon compound of variable structure (e.g., halogen derivatives of propanal, propanone, and propane) and p -aminobenzoyl-L-glutamic acid to yield folic acid

glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology Glutathione transporter as a target

IUPAC-IUB Joint Commission on Biochemical Nomenclature

glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology Glutathione transporter as a target

Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions

glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology Glutathione transporter as a target

doi: 10.1126/science.1171242

glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology Glutathione transporter as a target

Affinity chromatography is based on the simple principle that every biomolecule recognize another natural or artificial molecule such as enzyme and substrate or antibody and antigen [2,7]

glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology Glutathione transporter as a target

You may also like

recommand products